Wolfe Research downgraded Kymera Therapeutics (KYMR) to Peer Perform from Outperform.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics falls -4.0%
- Kymera Therapeutics price target raised to $117 from $80 at B. Riley
- Kymera Therapeutics price target raised to $103 from $70 at RBC Capital
- Kymera Therapeutics price target raised to $110 from $65 at Stephens
- Kymera Therapeutics’ KT-621 in dermatitis granted Fast Track Designation by FDA